Personalized medicine comes to autoimmune disease
Our technology platform screens millions of ‘drug-like’ molecules with sophisticated computational algorithms and 3-D models for their ability to dock within domains of a specific HLA protein. Beyond measuring target engagement, the in silico platform can help predict selectivity vs. off-target HLAs. The “hits” arising from our analyses enable rational drug design to develop drug candidates for optimal blockade of the HLA. Our lead drugs are extensively characterized with in vitro and in vivo biology with specific HLA-targeted assays and models.
Our platform allows us to develop a pipeline of drugs targeted against each HLA molecule that confers risk for a given autoimmune disease.
